Microbiome Guided Platform
The first system translating infant microbiome ecology into actionable nutrition decisions. No existing infant formula product integrates biological data at this level.
Investors & Partners
Investing in the Future of Personalized Infant Nutrition
Auralis is building the world's first microbiome- and infant host genetic DNA-guided infant nutrition platform — combining biology, AI, and scalable manufacturing into a defensible clinical-grade personalization engine.
Why Auralis Is a Unique Investment
Four defensible pillars in a single platform.
Predictive AI Engine
Adaptive formulation that evolves with infant development. Proprietary algorithms translate biological signals into precise nutritional blueprints with continuous refinement.
Personalized Manufacturing
Small-batch modular production at industrial scale. The manufacturing platform itself is a core IP asset, enabling personalization that legacy mass-production systems cannot achieve.
Clinical Validation Pathway
Structured FDA/EMA-aligned regulatory strategy, with feasibility validated and clinical pilots planned. Evidence generation model designed for continuous strengthening.
Market Opportunity
A category-defining opportunity.
$75B+
Global Infant Formula Market
$20B+
Personalized Nutrition Market
Growing at ~12% CAGR
130M
Births per Year Worldwide
Annual global opportunity window
$2K+ LTV
Per Family
Subscription-driven model
Competitive Landscape
Why Auralis Has No Direct Competitor
No existing formula company combines microbiome sequencing, genetic analysis, and AI-driven personalization into a single adaptive platform.
| Formula Type | Differentiation Approach |
|---|---|
| Traditional Formula | Standardized — mass-produced, one-size-fits-all |
| Organic Formula | Ingredient differentiation — organic sourcing, no structural change |
| Plant-Based Formula | Sourcing differentiation — alternative protein base |
| Auralis | Biological personalization platform — microbiome + infant host genetics + AI |
Partnership Opportunities
Where strategic collaboration accelerates the platform.
Clinical Research Partners
Hospitals, NICU programs, pediatric centers, and clinical research organizations.
- Participate in clinical validation programs
- Early life nutrition trials
Manufacturing Partners
Infant formula production facilities and precision blending platforms.
- Collaborate on scalable personalized manufacturing
Technology & Data Partners
AI, genomics, and microbiome data platforms.
- Co-develop the next generation of personalization technology
Strategic Investors
Nutrition innovation funds, preventive health platforms, and microbiome-focused investors.
- Join the first movers in personalized infant nutrition
Contact & Meeting Request
Personalized infant nutrition begins with collaboration.
Reach out to discuss investment, strategic partnership, or clinical collaboration.
investors@auralis.care-
Business Partnershipspartnerships@auralis.care
-
Clinical Programsclinical@auralis.care
-
General Contactinfo@auralis.care
Thank you, your message has been received.